Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.

Journal of medical economics

Volumn 16, Issue 2, 2013, Pages 278-288

  Xie, Jipan ^a   Diener, Melissa ^b   De, Gourab ^b   Yang, Hongbo ^b   Wu, Eric Q ^b   Namjoshi, Madhav ^b  

^a ANALYSIS GROUP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LETROZOLE; NITRILE; RAPAMYCIN; TRIAZOLE DERIVATIVE;

ARTICLE; BREAST TUMOR; BUDGET; CHEMISTRY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; UNITED STATES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BUDGETS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; NITRILES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TREATMENT FAILURE; TRIAZOLES; UNITED STATES;

EID: 84879016199     PISSN: None     EISSN: 1941837X     Source Type: None    
DOI: 10.3111/13696998.2012.749788     Document Type: Article

References (0)